Authors


Elizabeth Buchbinder, MD,

Latest:

Dr Buchbinder on Treatment With Nivolumab Maintenance Following irAEs in Melanoma

Elizabeth Buchbinder, MD, discusses the investigation of treatment with nivolumab maintenance therapy in patients with melanoma who experienced severe immune-related adverse effects associated with combination therapy with nivolumab and ipilimumab.


Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS

Latest:

Dr. Talwar on the Utility of Immunotherapy in Metastatic Urothelial Carcinoma

Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.


June-Wha Rhee, MD

Latest:

Dr. Rhee on the Benefit of Zanubrutinib Vs Ibrutinib in R/R CLL

June-Wha Rhee, MD, discusses the benefit of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, as well as the incidence of cardiac disorders associated with the BTK inhibitors.


Jane Lowe Meisel, MD

Latest:

Dr Meisel on the Impact of Endocrine Therapy–Related Toxicities on QOL in ER+/HER2– Breast Cancer

Jane L. Meisel, MD, discusses the impact of toxicities associated with endocrine therapy on quality of life as reported by patients with metastatic breast cancer.


Usman Ali Akbar, MD

Latest:

Dr. Akbar on the Efficacy of Monoclonal Antibodies Across Various Trials in R/R ALL

Usman Ali Akbar, MD, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia.


Kai-Keen Shiu, MD

Latest:

Dr Shiu on the FDA Approval of Pembrolizumab Plus Chemotherapy in Advanced HER2– Gastric/GEJ Adenocarcinoma

Kai-Keen Shiu, MD, discusses the significance of the FDA approval of pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment in patients with locally advanced, unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.



Chan Cheah, MBBS

Latest:

Dr. Cheah on the Investigation of BGB-11417 With or Without Zanubrutinib in CLL

Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.


Ashley Ross, MD, PhD, Northwestern Medicine

Latest:

Operational Processes and Challenges

Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.


Jason Brayer, MD, PhD

Latest:

Dr. Brayer on the Promise of BiTEs in Multiple Myeloma

Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.


AdventHealth Cancer Institute

Latest:

Novel Detection Methods May End Chemotherapy for Patients With CRC

A new genetic test that may allow patients with colorectal cancer to avoid chemotherapy after tumor resection is under investigation at AdventHealth Cancer Institute in Orlando, Florida.


Danielle E. Marcotulli, APN, John Theurer Cancer Center

Latest:

Evolving Treatment Landscape of Myelofibrosis

Closing out their discussion on myelofibrosis management, experts from the John Theurer Cancer Center consider novel therapies under investigation and the future treatment paradigm.


Anant Ramaswamy, MD

Latest:

Dr. Ramaswamy on Capecitabine and Irinotecan Monotherapy in Gallbladder Cancer

Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.


Coral O. Omene, MD, PhD

Latest:

Dr Omene on the Importance of Access to Breast Cancer Screenings in Underserved Populations

Coral O. Omene, MD, PhD, discusses the need to improve early access to breast cancer screenings for patients in underserved populations and recent updates to the National Comprehensive Cancer Network Guidelines on breast cancer screening.



Krina K. Patel, MD, MSc

Latest:

Treatment Considerations and Sequencing in Multiple Myeloma

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.


Kevin Zarrabi, MD

Latest:

Dr Zarrabi on Questions Regarding the Use of Triplet Therapy in Prostate Cancer

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses remaining questions regarding treatment consisting of triplet therapy in patients with metastatic castration-sensitive prostate cancer.


Susan Faye Dent, MD

Latest:

Dr. Dent on the Clinical Implications of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer

Susan Faye Dent, MD, discusses the clinical implications of the phase 3 MONALEESA-2 trial in hormone receptor–positive, HER2-negative breast cancer.


Martine Extermann, MD, PhD

Latest:

Dr. Extermann on the Significance of Novel Treatment Options in HER2+ Breast Cancer

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.


Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

Latest:

The Evolving Treatment Landscape of Biliary Tract Cancers

Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.


John L. Hays, MD, PhD

Latest:

Dr Hays on Unmet Needs in CRC

John L. Hays, MD, PhD, discusses unmet needs for patients with colorectal cancer and future directions for research in this disease.


Wesley J. Talcott, MD, MBA

Latest:

Dr Talcott on Treatment De-Escalation in Elderly Patients With Breast Cancer

Wesley J. Talcott, MD, MBA, discusses the importance of de-escalating therapy in patients with breast cancer, highlighting use of personalized treatment approaches.


Lakshmi Rajdev, MD, MS

Latest:

Dr. Rajdev on Detecting HER2 Positivity in GI Cancer

Lakshmi Rajdev, MD, MS, discusses detecting HER2 positivity in patients with gastrointestinal cancers.


Michal F. Segal, RN

Latest:

Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.


Cristina Lopez-Peñalver, MD

Latest:

Reviewing Best Practices in the Surgical Management of Breast Cancer: Post-Surgery Outcomes in Stage IV Disease

In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.


Nikhil Wagle, MD

Latest:

Direct Partnership With Patients May Accelerate Cancer Research and Precision Oncology

During the past several decades, cancer research has produced revolutionary discoveries leading to dramatic results for many patients.


Lilyana Angelov, MD

Latest:

Clinical Updates for the Management of Lung Cancer Brain Metastases

As improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.


Yayi Zhao

Latest:

Zhao on Existing Medical Conditions and Cancer Clinical Trial Enrollment

Yayi Zhao, discusses how the prevalence of existing medical conditions and clinical factors may vary by race and effect eligibility for enrollment in clinical trials in patients with cancer.


Lisa Langenderfer

Latest:

Physicians Must Become Advocates to Play a Role in Community Oncology’s Future

Although some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.


Brian Ramnaraign, MD

Latest:

Dr Ramnaraign on Retrospective Data For irAEs in Older Patients With Kidney Cancer

Brian H. Ramnaraign, MD, discusses findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney cancer.